FMX103 minocycline foam 1.5% + Vehicle foam
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Facial Papulopustular Rosacea
Conditions
Facial Papulopustular Rosacea
Trial Timeline
Jun 1, 2017 → Jul 31, 2018
NCT ID
NCT04608500About FMX103 minocycline foam 1.5% + Vehicle foam
FMX103 minocycline foam 1.5% + Vehicle foam is a phase 3 stage product being developed by Vyne Therapeutics for Facial Papulopustular Rosacea. The current trial status is completed. This product is registered under clinical trial identifier NCT04608500. Target conditions include Facial Papulopustular Rosacea.
What happened to similar drugs?
4 of 7 similar drugs in Facial Papulopustular Rosacea were approved
Approved (4) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03142451 | Phase 3 | Completed |
| NCT04608500 | Phase 3 | Completed |
Competing Products
13 competing products in Facial Papulopustular Rosacea
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BOTOX | AbbVie | Approved | 43 |
| OnabotulinumtoxinA + KYBELLA | AbbVie | Approved | 47 |
| BOTOX®/VISTABEL® | AbbVie | Approved | 43 |
| Erenumab Prefilled Syringe | Amgen | Approved | 43 |
| Rapamune | Pfizer | Phase 1 | 29 |
| EMLA Cream | Sanofi | Phase 3 | 40 |
| Diflucortolone valerate (BAY866146) | Bayer | Pre-clinical | 23 |
| Botulinum toxin type A | Ipsen | Phase 3 | 37 |
| IPN10200 + IPN10200 Placebo + Dysport | Ipsen | Phase 1/2 | 36 |
| IPN59011 + Azzalure + Placebo | Ipsen | Phase 1 | 18 |
| Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4) | Baxter | Phase 2 | 32 |
| Metyrosine + Placebo | Bausch Health | Phase 2 | 21 |
| FMX103 minocycline foam 1.5% + Vehicle foam | Vyne Therapeutics | Phase 3 | 30 |